Arbutus Biopharma Corp. (NASDAQ: ABUS) stock gained by 2.43% at last close whereas the ABUS stock price surges by 14.54% in the pre-market trading.Arbutus Biopharma Corporation is a publicly listed pharmaceutical firm whose primary goal is to find, develop, and commercialize a treatment for chronic hepatitis B virus (HBV) infection.
What is happening?
Five abstracts from ABUS will be presented at the European Association for the Study of the Liver’s International Liver Congress. Professor Man-Fung Yuen, Deputy Head of Department, Chief of Division of Gastroenterology and Hepatology, Master of Lap Chee, University of Hong Kong, and lead researcher of AB-729’s Phase 1a/1b clinical trial, gave an oral late-breaker presentation (Presentation LBO-2764) named, “Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Professor Yuen stated that AB-729 continues to show substantial mean HBsAg decrease across all dosages and dosing intervals, as well as a positive safety and tolerability profile, with a persistent plateau phase.
Professor Yuen commented,
These findings continue to show that AB-729 reduces HBsAg in a consistent and comparable manner across all dosages and dosing intervals, according to Professor Yuen. Importantly, AB-729 was usually well accepted and safe. He feels that these findings encourage further research into AB-729 as a potential breakthrough in the treatment of chronic HBV.
- At week 44, AB-729 dosed at 60 mg per 8 weeks had a mean HBsAg decrease of -1.87 log10 IU/mL, which was equivalent to 60 mg every 4 weeks.
- In 75 percent of treated patients, AB-729 reduced HBsAg levels below 100 IU/ml, and enhanced HBV-specific immune responses in 3/5 evaluable cases.
- HBV RNA and all HBsAg isoforms were reduced by AB-729, indicating wide target engagement.
- After 48 weeks of treatment, AB-729 showed a satisfactory safety and tolerability profile.
- Preclinical studies on AB-836 show that it has the potential to be more effective and have a better resistance profile than prior generation capsid inhibitors.